Larimar Therapeutics
clinical development plan | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
16 of 44
Related slides by other companies
Alkermes
Investor Day
March 2021
development plan seek early clinical evidence of activity synaptic and assessments are core components of the early clinical development plan and program decision making early clinical development plan objectives phase study planned initiation phase sad mad planned initiation identify differences in synaptic between healthy volunteers and patients with neurodegenerative diseases and inform indication selection determine relationship and in healthy volunteers determine effects on select phase basket studies in and neurodegenerative disorders confirm effect on of and function indications and for proof of concept studies sad single ascending dose mad multiple ascending dose pharmacodynamic maximum tolerated dose | Alkermes
BenevolentAI
Investor Presentation
October 2022
ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI
Erasca
Investor Presentation
January 2024
clinical development plan generates multiple ways to win for patients | Erasca
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights